The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis
The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis
OBJECTIVE: To evaluate the effect of disease-modifying antirheumatic drugs (DMARDs) on the likelihood of patients with rheumatoid arthritis (RA) developing septic arthritis (SA). METHODS: The United Kingdom General Practice Research Database (GPRD) was used to identify adults with RA, and age-, sex-, and practice-matched control subjects. Subjects were studied between 1987 and 2002. The risk of developing SA (excluding infected joint replacements) for individuals with RA was calculated and the effect of DMARD use determined. RESULTS: A total of 136,977 subjects (34,250 patients with RA, 102,747 controls) were identified. SA was identified in 345 subjects, of which 321 (236 in patients with RA, 85 in controls) cases occurred during the study period. The incidence rate of SA was 12.9 times higher in subjects with RA than in those without (95% confidence interval [95% CI] 10.1-16.5, P < 0.001). The incident rate ratios (IRRs) for developing SA while receiving DMARDs compared with receiving no DMARDs were different for different medications. Penicillamine (adjusted IRR 2.51, 95% CI 1.29-4.89, P = 0.004), sulfasalazine (adjusted IRR 1.74, 95% CI 1.04-2.91, P = 0.03), and prednisolone (adjusted IRR 2.94, 95% CI 1.93-4.46, P < 0.001) were associated with an increased incidence of SA when compared with not receiving any DMARD. The use of other DMARDs including methotrexate showed no such effect. CONCLUSION: Individuals with RA have an increased risk of developing SA. This increased risk can be attributed to both the disease process and the use of DMARDs
incidence, adult, bone, development, rheumatoid arthritis, risk, research, methods, disease
1151-1157
Edwards, C.J.
dcb27fec-75ea-4575-a844-3588bcf14106
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Fisher, D.
ecf01fcd-f5ea-4089-ac75-9806c7afecdf
Field, M.
8ecc8fff-737b-48f0-b333-98e230f1206e
Van Staa, T.P.
31b8bfb4-4e1b-4a48-a5a6-90ca601b94af
Arden, N.K.
23af958d-835c-4d79-be54-4bbe4c68077f
2007
Edwards, C.J.
dcb27fec-75ea-4575-a844-3588bcf14106
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Fisher, D.
ecf01fcd-f5ea-4089-ac75-9806c7afecdf
Field, M.
8ecc8fff-737b-48f0-b333-98e230f1206e
Van Staa, T.P.
31b8bfb4-4e1b-4a48-a5a6-90ca601b94af
Arden, N.K.
23af958d-835c-4d79-be54-4bbe4c68077f
Edwards, C.J., Cooper, C., Fisher, D., Field, M., Van Staa, T.P. and Arden, N.K.
(2007)
The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis.
Arthritis Care & Research, 57 (7), .
Abstract
OBJECTIVE: To evaluate the effect of disease-modifying antirheumatic drugs (DMARDs) on the likelihood of patients with rheumatoid arthritis (RA) developing septic arthritis (SA). METHODS: The United Kingdom General Practice Research Database (GPRD) was used to identify adults with RA, and age-, sex-, and practice-matched control subjects. Subjects were studied between 1987 and 2002. The risk of developing SA (excluding infected joint replacements) for individuals with RA was calculated and the effect of DMARD use determined. RESULTS: A total of 136,977 subjects (34,250 patients with RA, 102,747 controls) were identified. SA was identified in 345 subjects, of which 321 (236 in patients with RA, 85 in controls) cases occurred during the study period. The incidence rate of SA was 12.9 times higher in subjects with RA than in those without (95% confidence interval [95% CI] 10.1-16.5, P < 0.001). The incident rate ratios (IRRs) for developing SA while receiving DMARDs compared with receiving no DMARDs were different for different medications. Penicillamine (adjusted IRR 2.51, 95% CI 1.29-4.89, P = 0.004), sulfasalazine (adjusted IRR 1.74, 95% CI 1.04-2.91, P = 0.03), and prednisolone (adjusted IRR 2.94, 95% CI 1.93-4.46, P < 0.001) were associated with an increased incidence of SA when compared with not receiving any DMARD. The use of other DMARDs including methotrexate showed no such effect. CONCLUSION: Individuals with RA have an increased risk of developing SA. This increased risk can be attributed to both the disease process and the use of DMARDs
This record has no associated files available for download.
More information
Published date: 2007
Keywords:
incidence, adult, bone, development, rheumatoid arthritis, risk, research, methods, disease
Organisations:
Dev Origins of Health & Disease
Identifiers
Local EPrints ID: 61074
URI: http://eprints.soton.ac.uk/id/eprint/61074
ISSN: 0893-7524
PURE UUID: 990edcca-da1a-4571-97be-73ce0f5e2ed7
Catalogue record
Date deposited: 08 Sep 2008
Last modified: 18 Mar 2024 02:44
Export record
Contributors
Author:
D. Fisher
Author:
M. Field
Author:
T.P. Van Staa
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics